NEXTGEN-TIL

Phase 1Cell therapy

VVall d'Hebron Institute of Oncology

NEXTGEN-TIL is one of 2 biologic programs targeting Immune Checkpoint Blockade. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Checkpoint BlockadeRecruiting

Immune Checkpoint BlockadePhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Immune Checkpoint Blockade

#DrugCompanyPhaseTrials

Interleukin 2

EEssen Biotech

Phase 1

1 2

NEXTGEN-TIL

VVall d'Hebron Institute of Oncology

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Immune Checkpoint Blockade

NCT05141474

Clinical

Trials by Indication[1]

Immune Checkpoint Blockade1 trial

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

Recruiting·VVall d'Hebron Institute of Oncology·Phase 1·NCT05141474·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NEXTGEN-TIL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NEXTGEN-TIL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NEXTGEN-TIL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vall d'Hebron Institute of Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: VVall d'Hebron Institute of Oncology

NEXTGEN-TIL

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Immune Checkpoint Blockade1 trial

References

Drug Info

Quick Facts

Related News